Research Analysts’ updated eps estimates for Tuesday, September 23rd:Aardvark Therapeutics (NASDAQ:AARD) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $15.00 target price on the stock, down from their previous target price of $17.00. Robert W. Baird currently has a $195.00 price target on the stock, down from their previous price target of $225.00. The firm currently has a $35.00 price target on the stock, up from their previous price target of $27.00. Canaccord Genuity Group Inc. currently has GBX 550 target price on the stock, down from their previous target price of GBX 865.